We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Intensity Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing an approach to treat solid tumor cancers. It leverages its DfuseRx technology platform to create proprietary drug formulations. Its product candidates have the potential to induce an adaptive... Intensity Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing an approach to treat solid tumor cancers. It leverages its DfuseRx technology platform to create proprietary drug formulations. Its product candidates have the potential to induce an adaptive immune response that attacks the injected and non-injected tumors. The Company's lead product candidate, INT230-6, is in development for the treatment of patients with solid tumors, such as sarcoma and breast cancer patients. The Company, through Merck Sharpe & Dohme (Merck), evaluates INT230-6 with pembrolizumab. In addition, it also evaluates the combination INT230-6 with Bristol-Myers Squibb's anti-CTLA-4 antibody, ipilimumab. It also has an agreement with the Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer (the INVINCIBLE study) (NCT04781725). Show more
Ask ADVFN Intelligence (AI)
Intensity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update PR Newswire SHELTON, Conn., Nov. 13, 2024 First patient dosed in randomized, Phase 2 study in...
Intensity Therapeutics Selected for Oral Podium Presentation in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society (Sarcomas) Meeting PR Newswire SHELTON, Conn., Nov...
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Announce the First Patient Dosed in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical...
Intensity Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference PR Newswire SHELTON, Conn., Sept. 4, 2024 SHELTON, Conn., Sept. 4, 2024 /PRNewswire/ -- Intensity...
Intensity Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update PR Newswire SHELTON, Conn., Aug. 8, 2024 First patient dosed in global randomized, Phase 3 study...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.115 | -3.49544072948 | 3.29 | 3.3985 | 2.8001 | 18794 | 3.1896426 | CS |
| 4 | -0.123 | -3.72953305033 | 3.298 | 3.44 | 2.8001 | 14125 | 3.22517753 | CS |
| 12 | -1.135 | -26.3341067285 | 4.31 | 4.35 | 2.8001 | 12221 | 3.58912038 | CS |
| 26 | -1.395 | -30.5251641138 | 4.57 | 5.275 | 2.8001 | 13634 | 4.28009584 | CS |
| 52 | 0.605 | 23.5408560311 | 2.57 | 11.44 | 2.0101 | 173321 | 6.64488791 | CS |
| 156 | -2.775 | -46.6386554622 | 5.95 | 11.44 | 2.0101 | 134917 | 6.56863198 | CS |
| 260 | -2.775 | -46.6386554622 | 5.95 | 11.44 | 2.0101 | 134917 | 6.56863198 | CS |
Monksdream
4 weeks ago
Monksdream
4 months ago
Monksdream
6 months ago
Jackmcc222
11 months ago
Invest-in-America
11 months ago
TaperT2
11 months ago
Invest-in-America
11 months ago
Monksdream
11 months ago
Jess070283
11 months ago
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
